|CUR -- Germany Stock|| |
EUR 0.92 0.026 2.75%
Mr. Jonathan Lloyd Jones was appointed as Chief Financial Officer of Neuralstem Inc. effective May 18 2015. Mr. Lloyd Jones has more than 25 years of corporate finance and business development experience. Mr. Lloyd Jones is a Chartered Accountant and holds a Masters of Business Administration from Wharton School of the University of Pennsylvania and a BSc from the University of Bradford
Age: 53 CFO Since 2015
49 6027 40 900 51 http://www.curasan.de
Lloyd Jones has a background in corporate finance, particularly in licensing and partnering initiatives and in instituting financial infrastructure. From January 2013 until October 2014, he served as Chief Financial Officer of Columbia Laboratories . Prior to that, from 2011 to 2012, Mr. Lloyd Jones served as Chief Financial Officer and Vice President of Corporationrationrationrate Development at TetraLogic Pharmaceuticals, a venturebacked pharmaceutical company. Additionally from 2006 to 2010, Mr. Lloyd Jones served as Vice President, Finance, at TransMolecular, a privatelyheld clinical stage biotech company.
The company has return on total asset (ROA)
of (13.06) %
which means that it has lost $13.06 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (42.32) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 265 K in total debt with debt to equity ratio (D/E) of 2.6 implying the company greatly relies on financing operations through barroing. curasan AG has Current Ratio of 2.1 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company was founded in 1988 and is based in Kleinostheim, Germany. curasan AG operates under Healthcare Products classification in Germany and traded on Frankfurt Stock Exchange.curasan AG (CUR) is traded on Frankfurt Stock Exchange in Germany. It is located in Lindigstrasse 4 and employs 36 people.
curasan AG Leadership Team
|William Oldaker, Director|
|David Castaneda, Executive|
|Stanley Westreich, Director|
|Karl Johe, Chairman|
|Scott Ogilvie, Director|
|Catherine Sohn, Director, Ph.D|
|Richard Garr, CEO|
|Richard Daly, CEO, MBA|
|Sandford Smith, Director|
|Jonathan Jones, CFO|
Stock Performance Indicators
Macroaxis portfolio users are unresponsive in their opinion about investing in curasan AG. What is your take regarding investing in curasan AG? Are you bullish or bearish?
and pair trading evaluation for curasan AG and Fielmann AG
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return